Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck & Moderna combine Keytruda + personalized mRNA vaccine

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Dec 13, 2022 1:01pm

93 Views

Post# 35168854

RE:RE:Merck & Moderna combine Keytruda + personalized mRNA vaccine

Quentin30 wrote: It doesn't need to be off the shelf, if tailored manufacturing can rapidly create that personalised treatment.

You're losing it Noteable. When personalised CAR-T therapies are available en masse, then it's a paradignm shift in treatment, and ONCY will only have had a year or two to shine...

so WHO is going to buy us out..?

Quentin we needed an other basher here. H.... HAPPY to see you back!

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"